Effusion Cytology
Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study
Internal Medicine Journal 2022 February 21 [Link] L Pairman, Lel Beckert, M Dagger, M J Maze Abstract Background: Cytological examination of pleural fluid has a good specificity but imperfect sensitivity for the diagnosis of malignant pleural effusion (MPE). Published estimates of sensitivity vary and predictors of false negative cytology are not well established. We aimed…
Read MoreAnalysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology
Cancer Cytopathology 2022 February 10 [Link] Amber Louw, Chris van Vliet, Joanne Peverall, Shane Colkers, Nathan Acott, Jenette Creaney, Y C Gary Lee, Siaw Ming Chai Abstract Background: The concept of mesothelioma in situ has been revisited and is a new World Health Organization diagnostic entity. The definition centers on ancillary techniques used in pleural…
Read MoreThe highlights of the 15th international conference of the international mesothelioma interest group – Do molecular concepts challenge the traditional approach to pathological mesothelioma diagnosis?
Lung Cancer 2021 November 6 [Link] Sonja Klebe, Francoise Galateau Salle, Rossella Bruno, Luka Brcic, Heather I Chen-Yost, Marie-Claude Jaurand Abstract Pathology plays an important role in diagnosing mesothelioma since radiological and clinical findings alone cannot distinguish mesothelioma reliably from its many mimics. The long-held gold standard for pathological diagnosis requires a tissue biopsy that,…
Read MoreCytological Diagnostic Procedures in Malignant Mesothelioma
Advances in Experimental Medicine and Biology 2021 November 18 [Link] Christian Biancosino, Lea Isabell Shari van der Linde, Guido Sauter, Florian Stellmacher, Marcus Krüger, Lutz Welker Abstract Malignant mesotheliomas (MM) are rare tumors with high mortality rates, whose incidence varies regionally and nationally, and the diagnosis is difficult. Histology-based diagnosis is considered the gold standard…
Read MoreEvidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology
Cancer Cytopathology 2021 September 3 [Link] Ilaria Girolami, Ersilia Lucenteforte, Albino Eccher, Stefano Marletta, Matteo Brunelli, Paolo Graziano, Pasquale Pisapia, Umberto Malapelle, Giancarlo Troncone, Aldo Scarpa, Tao Huang, Liron Pantanowitz Abstract Cytology effusions are often the only material available for diagnosing malignant pleural mesothelioma (MPM). However, the cytomorphological features alone are not always diagnostic, and…
Read MoreState of the art cytology of pleural fluid, focusing on the diagnosis of mesothelioma
Cytopathology 2021 September 1 [Link] Sara E Monaco, Luka Brcic, Sanja Dacic Abstract Objective: Mesothelioma has always been a challenging diagnosis to render in body cavity cytology samples. This review is a timely update on pleural fluid cytology and ancillary studies that should be considered in the diagnosis of mesothelial proliferations, specifically mesotheliomas. Methods: Information…
Read MoreThe value of cytology in distinguishing malignant mesothelioma: An institutional experience of 210 cases reclassified according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC)
Cytopathology 2021 May 28 [Link] Patrizia Straccia, Daniele Magnini, Rocco Trisolini, Filippo Lococo, Marco Chiappetta, Alessandra Cancellieri Abstract Objective: Malignant mesothelioma (MM) is usually diagnosed by histological examination of tissue samples; however, effusion cytology offers an opportunity to identify a strong possibility for mesothelioma diagnosis at an early stage. We conducted a retrospective analysis of…
Read MoreDiagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology
Cytopathology 2021 May 25 [Link] Amber Louw, Y C Gary Lee, Nathan Acott, Jenette Creaney, Chris van Vliet, Siaw Ming Chai Abstract Objective: To assess the utility of BRCA1-associated protein 1 (BAP1) immunohistochemistry (IHC) for the diagnosis of malignant pleural mesothelioma (MPM) in fluid samples with atypical cytology. Methods: Pleural fluid samples with an atypical…
Read MoreTesting for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology
Cancer Cytopathology 2020 July 17 [Link] Martin Chevrier, Sara E Monaco, Jacob A Jerome, Francoise Galateau-Salle, Andrew Churg, Sanja Dacic Abstract Background: A number of ancillary tests have been developed that aid in the diagnosis of mesothelioma in cytology specimens. The aim of this retrospective study was to determine whether testing for BAP1 and CDKN2A/p16…
Read MoreGenomic-based Ancillary Assays Offer Improved Diagnostic Yield of Effusion Cytology With Potential Challenges in Malignant Pleural Mesothelioma
Pathology International 2020 June 15 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Kazuki Nabeshima Abstract BRCA1-associated protein 1 (BAP1) or methylthioadenosine phosphorylase (MTAP) immunohistochemistry (IHC) or 9p21 fluorescence in situ hybridization (FISH) are useful for the diagnosis of malignant pleural mesothelioma (MPM). However, the effect…
Read More